Outlook for RNAi, 2007 - siRNA and miRNA in biology, diagnostics and therapeutics

RNAi-based screens have provided new opportunities for the discovery and validation of novel therapeutic targets in areas such as cancer and infectious diseases. Since 2005, enormous strides have also been made in the development of RNAi-based therapeutic products, bringing them significantly closer to the market.

‘Outlook for RNAi 2007’ is a new report which provides a detailed insight into the most effective use of this novel technology in the drug discovery and development process. It puts into context where RNAi technology is being used as a tool of choice within academia and the pharma industry for functional genomic studies, drug target discovery and mechanism of action studies. The development status RNAi based therapeutics is covered in detail, highlighting the key companies in the field, outlining their pipelines and describing the results of completed clinical trials.

Understand how RNAi technology is being used to improve drug attrition rates and develop new therapeutic

agents, and ensure that you are up-to-date with developments in this advancing field.

Key findings

• The RNAi market is a relatively immature with global sales of approximately $447 million in 2006. It is projected to reach $0.9 billion by 2010, a compound annual growth rate (CAGR) of 19% between 2006-2010.

• One of the main reasons for RNAi’s popularity stems from its utility as a molecular biology tool enabling the in vivo functional analysis of thousands of genes. Recent advances in the field include the design of new libraries of RNAi effectors, delivery systems and read-out methods.

• In 2005, delivering RNAi triggers was the biggest obstacle in creating effective RNAi-based therapies. Subsequently, research into new and effective delivery methods has taken place at a frantic pace, although there are still major issues to be addressed.

The first human trials of a systemic RNAi-based therapeutic were initiated in 2007 by Quark Biotech.

• In the last two years, a more thorough understanding of the mechanism of action and intracellular pathways of miRNA has developed. miRNA is now an alternative gene knock-down technology that is being applied in research and for therapeutic and diagnostic applications.

Key questions answered

• What will the growth of the RNAi market be over the next 5 years?

• Who are the leading players in the RNAi market?

• How are big pharma companies capitalizing on this technology through strategic alliances with specialized

players?

• Which areas of therapeutic interest are being explored with RNAi-based agents?

• What are the Intellectual Property implications of RNAi research?

• What challenges must be overcome for RNAi technology to yield commercially viable therapeutics and make a

substantial improvement to drug-attrition rates?

Key issues examined in this report

• The value and breakdown of sub-sector performances of the RNAi market between 2006-2015.

• The therapy areas, progress of clinical research, potential drug sales and patent position of companies at the forefront of RNAi-based therapeutics.

• The relative strengths and weaknesses of different approaches to RNAi delivery and selectivity.

• The key trends that are currently affecting the RNAi market such as the development of new reagents, availability of custom synthesized siRNA, development of RNA microarrays and their impact on the R&D process

• The development of miRNA for diagnostic and therapeutic purposes.

Format PDF, Pages 244, June 2007
Table of Contents
Price: $2,875.00 / GBP1,437.50